WallStSmart

Nuwellis Inc (NUWE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target

Nuwellis Inc stock (NUWE) is currently trading at $1.10. Nuwellis Inc PS ratio (Price-to-Sales) is 0.31. Analyst consensus price target for NUWE is $11.00. WallStSmart rates NUWE as Sell.

  • NUWE PE ratio analysis and historical PE chart
  • NUWE PS ratio (Price-to-Sales) history and trend
  • NUWE intrinsic value — DCF, Graham Number, EPV models
  • NUWE stock price prediction 2025 2026 2027 2028 2029 2030
  • NUWE fair value vs current price
  • NUWE insider transactions and insider buying
  • Is NUWE undervalued or overvalued?
  • Nuwellis Inc financial analysis — revenue, earnings, cash flow
  • NUWE Piotroski F-Score and Altman Z-Score
  • NUWE analyst price target and Smart Rating
NUWE

Nuwellis Inc

NASDAQHEALTHCARE
$1.10
$0.01 (-0.90%)
52W$0.96
$47.88
Target$11.00+900.0%

📊 No data available

Try selecting a different time range

WallStSmart

Smart Analysis

Nuwellis Inc (NUWE) · 9 metrics scored

Smart Score

29
out of 100
Grade: F
Avoid
Investment Rating

Category Performance

WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.

Investment Thesis

Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.

Nuwellis Inc (NUWE) Key Strengths (2)

Avg Score: 10.0/10
Price/SalesValuation
0.3110/10

Paying less than $1 for every $1 of annual revenue

Price/BookValuation
0.9810/10

Trading below book value, meaning the market prices it less than net assets

Supporting Valuation Data

Price/Sales (TTM)
0.31
Undervalued
EV/Revenue
0.219
Undervalued
NUWE Target Price
$11
255% Upside

Nuwellis Inc (NUWE) Areas to Watch (7)

Avg Score: 0.7/10
Return on EquityProfitability
-467.10%0/10

Company is destroying shareholder value

Operating MarginProfitability
-121.60%0/10

Losing money on operations

Revenue GrowthGrowth
-6.30%0/10

Revenue declining -6.30%, a shrinking business

EPS GrowthGrowth
-99.20%0/10

Earnings declining -99.20%, profits shrinking

Profit MarginProfitability
-202.80%0/10

Company is losing money with a negative profit margin

Institutional Own.Quality
4.99%2/10

Very low institutional interest at 4.99%

Market CapQuality
$2M3/10

Micro-cap company with very limited liquidity and high volatility

Nuwellis Inc (NUWE) Detailed Analysis Report

Overall Assessment

This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 0.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.

The Bull Case

The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.31), Price/Book (0.98) suggest the stock is attractively priced.

The Bear Case

The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -6.30%, EPS Growth at -99.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -467.10%, Operating Margin at -121.60%, Profit Margin at -202.80%.

Key Dynamics to Monitor

Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -467.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -6.30% needing to reaccelerate.

Risk Considerations

Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.

Bottom Line

Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.

Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.

NUWE Price-to-Sales(PS) Ratio Chart

Historical valuation based on market cap ÷ trailing 12-month revenue

NUWE's Price-to-Sales ratio of 0.31x trades at a deep discount to its historical average of 10.19x (38th percentile). The current valuation is 100% below its historical high of 152.08x set in Jan 2014, and 1450% above its historical low of 0.02x in Nov 2022. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.

Compare NUWE with Competitors

Top MEDICAL DEVICES stocks by market cap

Compare any two stocks →

WallStSmart Analysis Synopsis

Data-driven financial summary for Nuwellis Inc (NUWE) · HEALTHCAREMEDICAL DEVICES

The Big Picture

Nuwellis Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 8M with 6% decline year-over-year. The company is currently unprofitable, posting a -202.8% profit margin.

Key Findings

Revenue Decline

Revenue contracted 6% YoY. Worth determining whether this is cyclical or structural.

Operating at a Loss

The company is unprofitable with a -202.8% profit margin. The path to breakeven will be the key catalyst.

What to Watch Next

Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Nuwellis Inc.

Bottom Line

Nuwellis Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.

This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Insider Transactions

Loading insider activity...

About Nuwellis Inc(NUWE)

Exchange

NASDAQ

Sector

HEALTHCARE

Industry

MEDICAL DEVICES

Country

USA

Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.